The development of direct-acting antiviral agents to treat chronic hepatitis C virus (HCV) infection, much needed clinically, has focused largely on inhibitors of two viral enzymes, the protease NS3 and NS5B, an RNA-dependent RNA polymerase essential for HCV replication. BMS-790052, identified using chemical genetics as a powerful specific HCV inhibitor, is a small-molecule inhibitor of a third viral molecule that has no known enzyme activity, the nonstructural protein 5A (NS5A). A team from Bristol-Myers Squibb this week reports on the discovery and virological profile of BMS-790052 and discloses clinical trial observations with this compound in normal healthy volunteers and HCV-infected subjects. These results establish proof-of-concept for HCV NS5A inhibition as a clinically relevant mechanism. In vitro data point to synergistic interactions with known HCV inhibitors, suggesting that cocktails of antiviral agents may be a viable therapeutic approach. [Letter p. 96; News & Views p. 42]
- An unsuspected drug target (News & Views p42, doi: 10.1038/465042a)
- Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect (Letter p96, doi: 10.1038/nature08960)
Recent Hot Topics
Sign up for Nature Research e-alerts to get the lastest research in your inbox every week.